
Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd’s exclusive license deal with VYNE Therapeutics Inc. on the oral BET inhibitor, TAY-B2 (now known as VYN201) forsees an upfront...

Nomi Biotech presents natural additive to preserve probiotics
Nomi Biotech sp zoo has presented a water-soluble formulation of curcumin with improved bioavailability in Frontiers in Nutrition allowing to...

Glioma drug combo turns tumours hot
Swiss researchers have shrinked one of the most lethal and untreatable types of cancer in mice using a combination treatment that proved safe in five...

Mosaic Therapeutics closes $28m series A financing
Oncology specialist Mosaic Therapeutics Ltd will use a $28m financing to push its preclinical pipeline of targeted oncology therapies for...

Cytovation ASA raises US$8m in Series A
A Series A follow-up financing of US$8m has brought up Cytovation ASA’s total Series A funding to US$28m. The Bergen-based company announced it will...

Mainz Biomed Partners with Microba Life Sciences
Leveraging a platform for measuring the human gut microbiome to discover and develop novel therapeutics for major diseases, Microba and Mainz Biomed...